Previous close | 7.75 |
Open | 7.77 |
Bid | 7.60 x 700 |
Ask | 7.65 x 2000 |
Day's range | 7.54 - 8.07 |
52-week range | 1.25 - 10.53 |
Volume | |
Avg. volume | 7,454,925 |
Market cap | 5.29B |
Beta (5Y monthly) | -0.23 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.08 |
Earnings date | 06 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 7.50 |
CULVER CITY, Calif., May 17, 2024--ImmunityBio, Inc. (NASDAQ: IBRX) today announced the publication of three podcasts with UroToday highlighting the company’s recent FDA approval of ANKTIVA® (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) and advances in bladder cancer research.
ImmunityBio ( NASDAQ:IBRX ) First Quarter 2024 Results Key Financial Results Net loss: US$134.1m (loss widened by 15...
CULVER CITY, Calif., May 07, 2024--ImmunityBio, Inc. (NASDAQ: IBRX) announced today that the drug substance (DS) has been completed and successfully qualified for "fill finish" (filling vials and finishing packaging), sufficient for 170,000 doses of 400mcg ANKTIVA (nogapendekin alfa inbakicept-pmln). Coupled with the recent announcement of a partnership with the Serum Institute of India (SII) for BCG availability, this provides the Company with a significant initial supply of ANKTIVA for commerc